1-20 of 72
Karl Ziegelbauer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Joerg Willuda, Hans-Henning Boehm, Jessica Pinkert, Mark Trautwein, Wolf-Dietrich Doecke, Oliver von Ahsen, Karl Ziegelbauer, Rienk Offringa, Bertolt Kreft, Philipp Beckhove
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-075.
DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-075
Published: 01 July 2019
View article
Journal Articles

Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance

Urs B. Hagemann, Sabine Zitzmann-Kolbe, Alexander Kristian, Carolyn Sperl, Christoph A. Schatz, Roger M. Bjerke, Alan S. Cuthbertson, Hartwig Hennekes, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3937.
DOI: https://doi.org/10.1158/1538-7445.AM2019-3937
Published: 01 July 2019
View article
Journal Articles

Abstract 3926: MSLN-TTC (BAY 2287411) induces immunogenic cell death and secretion of pro-inflammatory cytokines in vitro and triggers an immune memory effect against a mouse tumor model

Urs B. Hagemann, Pascale LeJeune, Jenny Karlsson, Christoph A. Schatz, Alan S. Cuthbertson, Hartwig Hennekes, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3926.
DOI: https://doi.org/10.1158/1538-7445.AM2019-3926
Published: 01 July 2019
View article
Journal Articles

Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Birgitta Sjöholm, Ilmari Ahonen, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Sanna-Maria Käkönen, Arne Scholz
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3936.
DOI: https://doi.org/10.1158/1538-7445.AM2019-3936
Published: 01 July 2019
View article
Journal Articles

Abstract 850: Mesothelin targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapeutic in mesothelin-positive cancers

Urs B. Hagemann, Alexander Kristian, Christine Ellingsen, Katrine Wickstroem, Anne Mobergslien, Jenny Karlsson, Roger M. Bjerke, Christoph Schatz, Christoph Kneip, Joachim Schuhmacher, Liv-Ingrid Oedegaardstuen, Hartwig Hennekes, Anna Tafuri, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan S. Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 850.
DOI: https://doi.org/10.1158/1538-7445.AM2018-850
Published: 01 July 2018
View article
Journal Articles

Abstract 855: Increased in vitro potency and in vivo efficacy of FGFR2-targeted thorium-227 conjugate (FGFR2-TTC) in combination with the ATR inhibitor BAY 1895344

Katrine Wickstroem, Urs B. Hagemann, Antje M. Wengner, Anette Sommer, Alexander Kristian, Christine Ellingsen, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Bertolt Kreft, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 855.
DOI: https://doi.org/10.1158/1538-7445.AM2018-855
Published: 01 July 2018
View article
Journal Articles

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Katrine Wickstroem, Urs B. Hagemann, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Bertolt Kreft, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 849.
DOI: https://doi.org/10.1158/1538-7445.AM2018-849
Published: 01 July 2018
View article
Journal Articles

Abstract 3935: Differentiation of multi-kinase inhibitors by in vivo transcript profiling: Potential implications for HCC therapy

Heidrun Ellinger-Ziegelbauer, Lukas Fiebig, Ludwig Schladt, Karl Ziegelbauer, Anette Sommer, Dieter Zopf
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3935.
DOI: https://doi.org/10.1158/1538-7445.AM2018-3935
Published: 01 July 2018
View article
Journal Articles

Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Oliver von Ahsen, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Pascale Lejeune, Hartwig Hennekes, Alan Cuthbertson, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 844.
DOI: https://doi.org/10.1158/1538-7445.AM2018-844
Published: 01 July 2018
View article
Journal Articles

Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents

Christoph A. Schatz, Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Charlotte Kopitz, Cem Elbi, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1780.
DOI: https://doi.org/10.1158/1538-7445.AM2018-1780
Published: 01 July 2018
View article
Journal Articles

Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL

Martin Lange, Antje Margret Wengner, Ulrich Bothe, Ulf Boemer, Reinhard Nubbemeyer, Holger Siebeneicher, Holger Steuber, Judith Guenther, Lisette Potze, Nicole Schmidt, Oliver Politz, Wolf-Dietrich Doecke, Eleni Lagkadinou, Thomas M. Zollner, Franz von Nussbaum, Dominik Mumberg, Andreas Steinmeyer, Michael Brands, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1887.
DOI: https://doi.org/10.1158/1538-7445.AM2018-1887
Published: 01 July 2018
View article
Journal Articles

Abstract LB-123: Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors

Sarah Glaeske, Franziska Huebner, Anna Anurin, Andreas Janzer, Sabine Zitzmann-Kolbe, Juliane Paul, Katja Glaeske, Sandra Berndt, Dominik Mumberg, Matyas Gorjanacz, Karl Ziegelbauer, Bertolt Kreft, Ningshu Liu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-123.
DOI: https://doi.org/10.1158/1538-7445.AM2018-LB-123
Published: 01 July 2018
View article
Journal Articles

Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model

Mari I. Suominen, Jukka P. Rissanen, Anniina Luostarinen, Katja M. Fagerlund, Birgitta Sjöholm, Esa Alhoniemi, Sanna-Maria Käkönen, Dominik Mumberg, Jussi M. Halleen, Karl Ziegelbauer, Arne Scholz
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5202.
DOI: https://doi.org/10.1158/1538-7445.AM2017-5202
Published: 01 July 2017
View article
Journal Articles

Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models

Antje Margret Wengner, Gerhard Siemeister, Ulrich Luecking, Julien Lefranc, Philip Lienau, Gesa Deeg, Eleni Lagkadinou, Li Liu, Sven Golfier, Christoph Schatz, Arne Scholz, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 836.
DOI: https://doi.org/10.1158/1538-7445.AM2017-836
Published: 01 July 2017
View article
Journal Articles

Abstract 1079: Preclinical activity of the FGFRinhibitor BAY 1163877 alone or in combination with antihormonal therapy in breast cancer

Oliver Politz, Peter Ellinghaus, Sebastian Bender, Sylvia Gruenewald, Franziska Siegel, Marie-Pierre Collin, Sabine Zitzmann-Kolbe, Dominik Mumberg, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1079.
DOI: https://doi.org/10.1158/1538-7445.AM2017-1079
Published: 01 July 2017
View article
Journal Articles

Abstract 160: High target binding affinity with long lasting cellular target engagement and high dose intermittent schedule of PI3K inhibitor copanlisib contribute to the potent anti-tumor activity and good safety profile

Amaury E. Fernández-Montalván, Victoria Georgi, James Vasta, Sarah Glaeske, Vera Puetter, Matthew B. Robers, Ursula Moenning, Andrea Sturz, Julien Lefranc, Karl Ziegelbauer, Michael Brands, Christian Stegmann, William J. Scott, Ningshu Liu
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 160.
DOI: https://doi.org/10.1158/1538-7445.AM2017-160
Published: 01 July 2017
View article
Journal Articles

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Gerhard Siemeister, Anne Mengel, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Amaury E. Fernández-Montalván, Simon Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Marion Hitchcock, Kirstin Meyer, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 287.
DOI: https://doi.org/10.1158/1538-7445.AM2017-287
Published: 01 July 2017
View article
Journal Articles

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich T. Luecking, Arne Scholz, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Philip Lienau, Gerhard Siemeister, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Michael Brands
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 984.
DOI: https://doi.org/10.1158/1538-7445.AM2017-984
Published: 01 July 2017
View article
Journal Articles

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Ulrich T. Luecking, Julien Lefranc, Antje Wengner, Lars Wortmann, Hans Schick, Hans Briem, Gerhard Siemeister, Philip Lienau, Christoph Schatz, Benjamin Bader, Gesa Deeg, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 983.
DOI: https://doi.org/10.1158/1538-7445.AM2017-983
Published: 01 July 2017
View article
Journal Articles

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, Carl F. Nising, Christoph Mahlert, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Stefanie Hammer, Simone Greven, Joachim Schuhmacher, Manuela Braun, Ruprecht Zierz, Sabine Wittemer-Rump, Axel Harrenga, Frank Dittmer, Frank Reetz, Heiner Apeler, Rolf Jautelat, Hung Huynh, Karl Ziegelbauer, Bertolt Kreft
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (21): 6331–6339.
DOI: https://doi.org/10.1158/0008-5472.CAN-16-0180
Published: 31 October 2016
View article
PDF
Includes: Supplementary data